Neumora announced that its two studies evaluating navacaprant in MDD (Koastal-2 and Koastal-3) were not statistically significant on their primary or key secondary endpoints. However, after a few trials, Neumora has dropped the development plans for the drug and is set to dismiss 35% of its workforce, according to a press release.
The kappa opioid receptor antagonist navacaprant did not show significant superiority over placebo in the week 6 change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores across the studies. Actually, in the Koastal-3 study, patients got even better on the placebo on the depression rating scale, Neumora said.
Neumora announced the results of the Koastal-1 study at the beginning of 2025, but the drug failed to turn out as well as they had hoped, causing the stock to drop by 80% at the time. Early Monday, in the wake of the Koastal-2 and Koastal-3 flops, the stock was down 45% to 98 cents. Overall, the Neumora share price has lost about 95% from its peak price in early 2025.
In its release, the company had nothing positive to say about navacaprant. Neumora is still “excited” by the prospect of other catalysts for its pipeline in the near term; however, with Alzheimer’s disease agitation, schizophrenia, and cardiometabolic disease trials expected to provide a readout soon, Chairman and CEO Paul L. Berns said.
With the Koastal trial’s failure comes word of layoffs. Neumora is aiming to save $10 million a year by cutting about 35% of its staff. It is hoping that the restructuring will lead to $2 million in write-off expenses. With the changes, Neumora’s cash runway should extend into the third quarter of 2027, the company said.
The V1a receptor antagonist NMRA-511 as a therapy for Alzheimer’s disease agitation, an M4 positive allosteric modulator, NMRA-898, a prospect for schizophrenia, and an NLRP3 inhibitor, NMRA-215, in obesity, are now part of the company’s pipeline.
Neumora was created by Arch Venture Partners and received $500 million of funding in October 2021. The company was founded with the premise that big breakthroughs in neuroscience and increased precision in targeting patients for trials would help to de-risk trials and increase the chances for good outcomes.
Neumora has announced plans to reduce approximately 35% of its workforce after disappointing late-stage results for Navacaprant, a key investigational therapy in the company’s neuroscience pipeline.
Neumora Responds to Navacaprant Trial Results
The workforce reduction comes after Neumora reported unfavorable outcomes from a late-stage clinical study involving Navacaprant.
The company expects the workforce reduction to generate meaningful cost savings over the coming years. By lowering operating expenses, management aims to preserve capital and extend the organization’s ability to fund ongoing research and development activities. Such measures are often implemented after major clinical setbacks to ensure that resources are allocated toward programs with the highest probability of success.
In addition to personnel reductions, leadership may evaluate other operational efficiencies, including adjustments to research priorities, facility utilization, and external partnerships. These actions can help create a more sustainable financial position during periods of uncertainty.
The Significance of Late-Stage Clinical Failures
Late-stage clinical trials represent one of the most critical and expensive phases of drug development. By the time a therapy reaches Phase 3 testing, companies have often invested hundreds of millions of dollars and years of scientific effort. A failure at this stage can have far-reaching consequences, affecting valuation, investor confidence, and future strategic planning.
Despite rigorous early-stage testing, many promising therapies fail to demonstrate sufficient efficacy in larger patient populations. These outcomes highlight the inherent risks involved in pharmaceutical innovation and the challenges of translating scientific hypotheses into approved medicines.
Impact on Employees and Corporate Culture
Large-scale workforce reductions can have a significant impact on organizational culture and employee morale. Remaining team members often face increased responsibilities as companies streamline operations and redefine priorities. Leadership teams must balance financial objectives with the need to maintain productivity, innovation, and engagement across the organization.
Supporting affected employees through severance packages, career transition assistance, and transparent communication has become a common practice within the biotechnology sector during restructuring periods.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
